At a glance
- Originator NPS Allelix
- Class Small molecules
- Mechanism of Action Nerve growth factor receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Neuropathic pain
Most Recent Events
- 12 Dec 2002 Discontinued - Preclinical for Neuropathic pain in USA (unspecified route)
- 15 Feb 2000 Preclinical development for Neuropathic pain in USA (Unknown route)